Disclosed is a hydrophilic dressing (200) having appropriate mechanical strength, comprising a composite material (100, 220) and a film (210). The composite material (100, 220) comprises a hydrophilic substrate material (110) and a compound (120) that promotes wound healing, wherein the hydrophilic substrate material (110) is a reaction product of a hydrophilic polymer, wherein the hydrophilic polymer comprises a hydrophilic monomer, a cross-linking agent and an inorganic silicon-oxygen compound, wherein the compound (120) that promotes wound healing is distributed in the hydrophilic substrate material (110).

Disclosed is a hydrophilic dressing (200) having appropriate mechanical strength, comprising a composite material (100, 220) and a film (210). The composite material (100, 220) comprises a hydrophilic substrate material (110) and a compound (120) that promotes wound healing, wherein the hydrophilic substrate material (110) is a reaction product of a hydrophilic polymer, wherein the hydrophilic polymer comprises a hydrophilic monomer, a cross-linking agent and an inorganic silicon-oxygen compound, wherein the compound (120) that promotes wound healing is distributed in the hydrophilic substrate material (110).

A formulation of foam thermosensitive hydrogel includes a thermosensitive hydrogel including synthetic polymeric material. The thermosensitive hydrogel has properties of changing phase from liquid to solid in high temperature and changing phase from solid to liquid in low temperature. The foam thermosensitive hydrogel having a predetermined surface tension is formed after mixing the thermosensitive hydrogel with air. The foam thermosensitive hydrogel has properties of increased volume and being semisolid. After injecting the foam thermosensitive hydrogel into a human body, the foam thermosensitive hydrogel changes phase form liquid to solid after temperature rises above LCST. The foam thermosensitive hydrogel injected into the human body becomes a solid, physical barrier between an injured site and surrounding tissue, thereby preventing adhesion from forming in the human body. A method of manufacturing foam thermosensitive hydrogel is also provided.

This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.

This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.

Mucoadhesive microgel compositions, which include an active agent (such as HB-EGF), are provided. Aspects of the invention include a microgel comprising a crosslinked poly(ethylene glycol) methyl ether methacrylate polymer comprising a mucoadhesive functionality. Also provided are methods of making and using the mucoadhesive microgel compositions, e.g., in therapeutic applications. In one embodiment, HB-EGF loaded mucoadhesive microgel compositions are provided, e.g., for prevention or treatment of mucositis conditions, such as therapy induced oral mucositis conditions.

Mucoadhesive microgel compositions, which include an active agent (such as HB-EGF), are provided. Aspects of the invention include a microgel comprising a crosslinked poly(ethylene glycol) methyl ether methacrylate polymer comprising a mucoadhesive functionality. Also provided are methods of making and using the mucoadhesive microgel compositions, e.g., in therapeutic applications. In one embodiment, HB-EGF loaded mucoadhesive microgel compositions are provided, e.g., for prevention or treatment of mucositis conditions, such as therapy induced oral mucositis conditions.

A medical device including an internal wetting agent and a copolymer of a silicone monomer and satisfying the following conditions: (1) that the internal wetting agent contains a copolymer of an open-chain compound having an acidic group and an open-chain compound having an amide group; (2) that the internal wetting agent is contained in the range of from 0.1 to 10% by mass with respect to the whole medical device; and (3) that the copolymer of a silicone monomer has a hydroxyl group and that the content ratio of the hydroxyl group in the silicone monomer is in the range of from 0.0005 to 0.01 equivalents/g. A medical device containing an internal wetting agent and having excellent transparency and hydrophilicity can be obtained.

A medical device including an internal wetting agent and a copolymer of a silicone monomer and satisfying the following conditions: (1) that the internal wetting agent contains a copolymer of an open-chain compound having an acidic group and an open-chain compound having an amide group; (2) that the internal wetting agent is contained in the range of from 0.1 to 10% by mass with respect to the whole medical device; and (3) that the copolymer of a silicone monomer has a hydroxyl group and that the content ratio of the hydroxyl group in the silicone monomer is in the range of from 0.0005 to 0.01 equivalents/g. A medical device containing an internal wetting agent and having excellent transparency and hydrophilicity can be obtained.

Provided are a superabsorbent polymer capable of exhibiting improved bacterial growth-inhibitory property without deterioration in physical properties of the superabsorbent polymer, such as water retention capacity and absorbency under pressure, or without an increase in the generation of dust, and a preparation method thereof. The superabsorbent polymer may include a base polymer powder including a crosslinked polymer of water-soluble ethylenically unsaturated monomers including acidic groups, of which at least a part is neutralized; and a surface-crosslinked layer which is obtained by additionally crosslinking the crosslinked polymer via a surface crosslinking agent to be formed on the surface of the base polymer powder, wherein the crosslinked polymer of the base polymer powder or the surface-crosslinked layer includes an antimicrobial agent including an organic acid salt having an aromatic ring inside the crosslinked structure thereof.